Vertex Enterprise Value Over E B I T D A from 2010 to 2025
| VRTX Stock | USD 508.99 2.75 0.54% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 207.43399136 | Current Value 217.81 | Quarterly Volatility 123.72839293 |
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.6 B, Gross Profit of 10 B or Other Operating Expenses of 11.8 B, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 7.39. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
Vertex | Enterprise Value Over E B I T D A |
Latest Vertex Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Vertex Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 79.27 | |
| Geometric Mean | 56.19 | |
| Coefficient Of Variation | 156.08 | |
| Mean Deviation | 103.26 | |
| Median | 34.40 | |
| Standard Deviation | 123.73 | |
| Sample Variance | 15,309 | |
| Range | 424 | |
| R-Value | 0.22 | |
| Mean Square Error | 15,638 | |
| R-Squared | 0.05 | |
| Significance | 0.42 | |
| Slope | 5.61 | |
| Total Sum of Squares | 229,631 |
Vertex Enterprise Value Over E B I T D A History
About Vertex Pharmaceuticals Financial Statements
Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 207.43 | 217.81 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.